VivoSeq
Other

Gut Microbiota

0

Pipeline Programs

6

Active Trials

1

Companies Involved

Gut Microbiota is an early-stage landscape with 0 programs across 1 company. The most active players are Biogen.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

3/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

32

clinical trials

Completed13 · 41%
Unknown status12 · 38%
Recruiting4 · 13%
Terminated1 · 3%
Not yet recruiting1 · 3%
Enrolling by invitation1 · 3%

Trial Activity

32 trials

Effect of Ezetimibe on Gut Microbiota
Recruiting·YYonsei University·Phase 4·NCT06784557·110 enrolled
Encapsulated Probiotics & Gut Microbiota
Not yet recruiting·UUniversity College Dublin·Phase 1·NCT07439978·50 enrolled
Tecfidera and the Gut Microbiota
Completed·Biogen logoBiogen·Phase 4·NCT02471560·36 enrolled
Eradication of Gut Microbiota
Completed·UUniversity Hospital, Gentofte, Copenhagen·Phase 1·NCT01633762·12 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)